SingleCare analyzed consumer prescription demand and fill data in the weeks leading up to shelter in place orders, beginning in March, and the subsequent months after the pandemic to see how COVID has impacted the healthcare trends of Americans.
SingleCare, a pharmacy savings company, analyzed consumer prescription demand and fill data in the weeks leading up to coronavirus shelter in place orders, beginning in March, and the months after the pandemic to see how COVID-19 has impacted the healthcare trends of Americans.
Antidepressant fills spike to new highs
According to the report, a drug group that has seen significant increases since the start of the pandemic is antidepressants. SingleCare has seen a nearly 50% increase in fills for antidepressants in the third week of June, a similar increase occurred in the third week of March when social distancing and sheltering in place began, the report says.
In a recent SingleCare survey of 1,000 U.S. respondents, 59% said COVID-19 has affected their mental health.
“Between the concern over job loss, isolation, and general anxiety, this growing trend in antidepressants over the past few months may well be due to the pandemic’s impact on mental health,” Ramzi Yacoub, Pharm.D., the chief pharmacy officer at SingleCare, says.
Cold and flu decline while allergy and asthma medications surge
SingleCare analyzed the top prescription fills by volume during the months of March to May 2020 and compared those figures to the fills during the same three month period in 2019.
Two trends found:
Compared to 2019, SingleCare saw a 41% increase in Albuterol, a common rescue inhaler, 35% increase in cetirizine (the generic version of Zyrtec), and a 44% increase in ibuprofen.
However, the company saw a decrease in fills for benzonatate, a common cough medicine, at 19%, and a 23% decrease in fills for oseltamivir, the generic version of Tamiflu.
Flu vaccinations increase by 500% from last year at the start of the pandemic
While cold and flu medications declined as a result of the pandemic, Americans rushed to the pharmacy for flu vaccines as the threat of COVID emerged.
However, as the COVID-19 outbreak in the U.S. spread, as did flu vaccine fills:
The access and affordability of healthcare during COVID-19
In a recent SingleCare survey of 1,000 U.S. consumers, 58% said they did not understand how their prescription medications were priced. SingleCare believes in transparency of healthcare pricing and helps consumers access lower prices on prescriptions so that they can continue to adhere to necessary medications, the report says.
After reviewing the drug categories of the prescription medications previously mentioned, SingleCare saw a decrease in the usual and customary (UNC) price for these medications when comparing the time periods of March to May 2020 with March to May 2019.
“Various factors can contribute to the pricing of prescriptions, such as demand, number of manufacturers, new generics or brand entrants into the market, and the cost of ingredients,” says Yacoub. “The increase in demand for antiasthmatics, antivirals, and antidepressants along with the impact of COVID-19 may have contributed to the overall reduction in the usual and customary cost of these drug groups.”
In addition, the survey revealed 21% stopped taking medications since the pandemic began, as a result of cost or access, and 27% opted to skip doctor’s appointments due to financial constraints created by the pandemic.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More